Pointcare Genomics Corporation announced this week it is the recipient of a $300,000 SBIR Phase I grant.

According to a release, the money from the National Cancer Institute will help develop technologies for detecting circulating cell-free methylated DNA for diagnosis of cancers.

“We are honored to receive NCI’s support for our ideas for developing innovative molecular diagnostic tests for rapid detection of cancers,” CEO and President Tonny Johnson said in a statement. “This contract from NCI will help us to develop these tests, ultimately helping physicians to make critical treatment decisions and improving quality of cancer patient care.”

Pointcare Genomics Corporation is a biotech company focused on developing innovative clinical diagnostic tests for the early detection, diagnosis and prognosis of human diseases such as cancers and heart diseases.